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Tissue epithelial cells actively signal the pres-
ence or absence of stress through the induction 
of   cytokines and surface ligands, which, in turn, 
  engage coactivating or inhibitory NK receptors 
expressed by eff   ector CTLs (for review see 
reference 1). One prominent pathway in this 
crosstalk between the tissue target and the eff  ector 
CTLs involves NKG2D (2–6) and its multiple 
  ligands: MICA/B (7) and ULBPs (8) in humans 
and Rae 1α-ε, H60, and MULT1 in mice (9–11). 
NKG2D exclusively associates in humans (4, 
12–14), in contrast to mice (15, 16), with the PI3 
kinase–bearing adaptor molecule DAP10 (4, 
12–14), which endows NKG2D with costimula-
tory properties for TCR activation (2, 7).
However, we recently reported that preexpo-
sure to IL-15, a cytokine up-regulated in in-
fl   ammatory and infectious conditions (17), 
enabled NKG2D to selectively unleash the cy-
tolytic properties of eff  ector CTLs, indepen-
dently of TCR specifi  city (2, 4). The arming of 
NKG2D by IL-15 to induce cytolysis in CTLs 
may be particularly relevant in the pathogenesis 
of T cell–mediated diseases, where IL-15 is up-
regulated by tissue target cells (for review see 
reference 1). A good example is celiac disease, 
where DQ2- and DQ8-restricted CD4+ T cell 
responses in the lamina propria to peptides de-
rived from dietary gluten are necessary (for re-
view see references 18 and 19) but not suffi   cient 
(20) to induce villous atrophy and malabsorption, 
the hallmarks of celiac disease (for review see 
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Celiac disease is an intestinal infl  ammatory disorder induced by dietary gluten in geneti-
cally susceptible individuals. The mechanisms underlying the massive expansion of inter-
feron 𝗄–producing intraepithelial cytotoxic T lymphocytes (CTLs) and the destruction of 
the epithelial cells lining the small intestine of celiac patients have remained elusive. We 
report massive oligoclonal expansions of intraepithelial CTLs that exhibit a profound ge-
netic reprogramming of natural killer (NK) functions. These CTLs aberrantly expressed 
cytolytic NK lineage receptors, such as NKG2C, NKp44, and NKp46, which associate with 
adaptor molecules bearing immunoreceptor tyrosine-based activation motifs and induce 
ZAP-70 phosphorylation, cytokine secretion, and proliferation independently of T cell 
receptor signaling. This NK transformation of CTLs may underlie both the self-perpetuating, 
gluten-independent tissue damage and the uncontrolled CTL expansion leading to malig-
nant lymphomas in severe forms of celiac disease. Because similar changes were detected in 
a subset of CTLs from cytomegalovirus-seropositive patients, we suggest that a stepwise 
transformation of CTLs into NK-like cells may underlie immunopathology in various chronic 
infectious and infl  ammatory diseases.
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references 21–23). Despite the dramatic expansion of intraepi-
thelial CTLs (IE-CTLs) in active celiac (AC) disease, their role 
was for a long time disregarded because gluten-  specifi  c IE-
CTLs could not be identifi  ed (for review see references 21 
and 22). A potential molecular basis for epithelial cell destruc-
tion by IE-CTLs and the slow and partial recovery of a normal 
mucosa after gluten exclusion (24, 25) was provided by the 
fi  nding that NKG2D expressed on IE-CTLs mediated cytolysis 
of stressed MICA/B-expressing enterocytes (4, 5).
However, because NKG2D could not induce other 
  eff  ector functions, such as cytokine secretion and proliferation 
in IE-CTLs (2, 4), several fi  ndings remained obscure. First, it 
was shown in AC disease that IE-CTLs   secreted high levels of 
IFN-γ (26, 27). Second, a long-term complication of celiac 
disease is “refractory sprue,” a severe diet-refractory condition 
associated with a massive infi  ltration of the diseased epithe-
lium by CTLs, which ultimately undergo malignant transfor-
mation into lymphomas (for review see references 21, 28, 
and 29). Collectively, these observations led us to hypothesize 
that IE-CTLs, in an intestinal environment favoring their 
chronic activation, may have undergone a dysregulation of 
their genetic program, resulting in the   aberrant expression of 
NK receptors associated with immuno  receptor tyrosine-based 
activation motif (ITAM)-bearing adaptor molecules capable 
of mediating proliferation and   cytokine secretion.
Here, we identify in celiac patients a massive expansion of 
a few IE-CTL clones that have undergone a genetic repro-
gramming of their signaling properties, which has essentially 
converted them into functional NK cells. The transcriptional 
signature of this reprogramming is the induction of a panoply 
of receptors and adapters normally restricted to the NK 
  lineage. One conspicuous example is CD94/NKG2C, which 
alone signals cell proliferation, cytokine secretion, and target 
killing through the ITAM-bearing adaptor molecule DAP12 
(30), also named KARAP (31), without a requirement for 
TCR engagement. In addition, its ligand HLA-E (32, 33) is 
strongly induced on celiac enterocytes, hence enabling full 
activation of intraepithelial NKG2C+ CTLs.
This broad acquisition of the NK signaling program in 
CTLs may signifi  cantly contribute to celiac intestinal immuno-
pathology, as it violates the well-established rule of cell-
  mediated immunity indicating that CTLs may not be able to 
proliferate, produce infl   ammatory cytokines, or kill unless 
their TCR specifi  cally recognizes antigen presented by MHC 
class I molecules on the target cell membrane.
RESULTS
Selective expansion of CTLs expressing activating 
CD94/NKG2C receptors in the intestinal epithelium 
of celiac patients
CD94/NKG2C receptors, which are classically absent in 
CTLs, were reported to be expressed in CMV-seropositive 
patients on a small subset of human CTLs of unknown speci-
fi  city (34, 35). In the normal intestinal epithelium, CD94 is 
expressed by a subset of IE-CTLs and associates predomi-
nantly with the inhibitory NKG2A subunit (36). Previous 
studies have reported a marked expansion of CD94+ IE-
CTLs in celiac disease (37). In this study, we sought to deter-
mine the nature, inhibitory or activating, of the NKG2 
subunit associated with CD94. Fig. 1 A shows that the inhib-
itory CD94/NKG2A receptor was markedly underrepresented. 
Thus, whereas  20% (n = 14; mean: 19 ± 11%) of healthy 
IE-CTLs expressed NKG2A, less than 6% of their celiac 
counterparts did, whether active (n = 16; mean: 5.5 ± 5.5%) 
or on a gluten-free diet (GFD; n = 10; mean: 3.5 ± 2.5%). 
In contrast, surface NKG2C, which was normally expressed 
at a very low frequency on healthy IE-CTLs (n = 12; mean: 
3.4 ± 4.4%), was found on the cell surface of a substantial 
proportion of IE-CTLs from AC patients (n = 22; mean: 
19.5 ± 13.8%; P < 0.0001; Fig. 1 B). In 7 out of 22 patients, 
the frequency of NKG2C+ IE-CTLs was >20% and was 
64% in one patient (Fig. 1 B). Notably, patients on GFD ex-
hibited a decrease, albeit not signifi  cant, in the frequency 
of NKG2C+ IE-CTLs (n  = 11; mean: 10.7 ± 6.5%; 
P = 0.16), suggesting that NKG2C expression remained in-
creased after   exclusion of gluten (Fig. 1 B). Importantly, 
NKG2A, when present, was never coexpressed with NKG2C, 
as reported previously (36, 38).
CD94/NKG2C is a heterodimeric receptor (for review 
see reference 39) whose surface expression depends on the 
expression of the signaling adaptor DAP12 (30). Because 
DAP12 expression might be regulated independently of 
NKG2C, we also stained NKG2C after membrane permeabi-
lization to detect intracellular NKG2C (Fig. 1 C). On   average, 
nearly 40% of the permeabilized IE-CTLs from   either patients 
with AC disease (n = 4; mean: 38.3 ± 28%; P = 0.0001) or 
on a GFD (n = 5; mean: 37 ± 17.7%; P < 0.0001) expressed 
NKG2C, whereas IE-CTLs from healthy controls did not 
(n = 8; mean: 2.3 ± 4.4%). This surprising fi  nding revealed a 
more profound dysregulation of NKG2C than anticipated by 
analysis of NKG2C on the cell surface of IE-CTLs, even in 
apparently symptom-free GFD patients.
Among the peripheral blood CD8+TCR-αβ+ of healthy 
individuals (peripheral blood CTLs [PB-CTLs]), CD94/
NKG2C+ CTLs were rarely detected (n = 8; mean: 0.4 ± 
0.1%), as reported previously (35). On average, the frequency 
in celiac samples (n = 19; mean: 1.6 ± 2.2%; P = 0.3) 
was not statistically diff  erent from healthy samples, although 
a few patients did exhibit unusual frequencies as high as 
5–10% (Fig. 1 D).
To further characterize CD94/NKG2C expression on 
celiac CTLs, we used tetramers of its ligand, HLA-E, loaded 
with an HLA-G leader peptide and demonstrated staining of 
99% of the NKG2C+ CTLs, as expected (Fig. 1 E). Interest-
ingly, however, the example shown in Fig. 1 E indicated 
that two subsets of NKG2C+ HLA-E tetramer+ CTLs were 
resolved based on the staining intensity with anti-NKG2C 
antibody and HLA-E tetramers, respectively. The nature of 
these subsets is unclear, but the data might indicate the 
  presence of another HLA-E binding CD94/NKG2 isoform, 
e.g., NKG2H or NKG2E, coexpressed with NKG2C (40). 
Tetramer staining was blocked by an anti-CD94 antibody, JEM VOL. 203, May 15, 2006  1345
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indicating that HLA-E recognition was exclusively mediated 
by CD94-bearing receptors.
Collectively, these results indicate that there is a selective 
up-regulation of activating CD94/NKG2C receptors on celiac 
IE-CTLs, potentially tipping the balance toward activation of 
CTL eff  ector function. Furthermore, our results suggest that 
expression of NKG2C persists partially   aftergluten exclusion.
CTL stimulation by NKG2C/DAP12 and costimulation by NKG2D
Because DAP12 is essential for CD94/NKG2C expression at 
the cell surface (30), we investigated whether DAP12 was 
present and formed a functional complex with CD94/
NKG2C in NKG2C+ IE-CTLs and PB-CTLs. As antici-
pated, DAP12 transcripts and protein were absent in normal 
IE-CTLs (not depicted). In contrast, DAP12 was expressed 
in fi  ve out of fi  ve NKG2C+ CTLs examined. A representa-
tive intracellular DAP12 staining is shown in the PB-CTLs of 
a patient with AC disease (Fig. 2 A). DAP12 was expressed 
at comparable levels in TCR-αβ+ T cells and in NK cells 
(TCR-αβ−). Furthermore, surface coimmunoprecipitation 
experiments performed on celiac IE-CTL clones that ex-
pressed both CD94/NKG2C and NKG2D showed that 
NKG2C was associated with DAP12, whereas NKG2D was 
associated with DAP10 (reference 4 and not depicted). 
Figure 1.  Selective expansion of IE-CTLs expressing activating 
CD94/NKG2C receptors in celiac disease. Representative fl  ow cyto-
metric data on freshly isolated TCR-αβ+CD8+ IE-CTLs or PB-CTLs from 
normal controls (Cntrl), AC patients, and celiac patients on a GFD are 
shown in the right panels. A scatter plot graph summarizing all samples 
investigated is shown on the right in A–D. (A) Decreased frequency of IE-
CTLs expressing inhibitory CD94/NKG2A receptors in AC patients and GFD 
patients. (B) Increased frequency of IE-CTLs expressing surface CD94/
NKG2C receptors in AC patients and GFD compared with controls. 
(C) Increased frequency of IE-CTLs expressing intracellular NKG2C protein 
(NKG2C IC) in AC patients and GFD compared with controls. (D) Propen-
sity toward an increased frequency of PB-CTLs expressing surface CD94/
NKG2C receptors in AC patients and GFD compared with controls. (E) CD94-
dependent HLA-E recognition by CD94/NKG2C+ CTLs. A representative 
example of HLA-E staining on gated TCR-αβ+CD8+ NKG2C+ CTLs is 
shown on freshly isolated PBLs. Left panel shows that incubation with 
anti-CD94 antibody before incubation with a HLA-E tetramer prevents 
staining with the HLA-E tetramer.1346  NK REPROGRAMMING OF CTLS | Meresse et al.
  Finally, stimulation of the IE-CTL clone by anti-NKG2C 
induced ZAP-70 phosphorylation (Fig. 2 B), as established 
previously with NK cells (41).
In a plate-bound antibody stimulation assay, NKG2C 
  engagement induced IFN-γ secretion (Fig. 2 C) as well as 
proliferation (Fig. 2 D) of celiac NKG2C+ CTLs. Notably, 
although NKG2D did not induce cytokine secretion and 
proliferation by itself, it did enhance NKG2C-mediated 
stimulation (Fig. 2, C, right panels, and D), thus acting as a 
costimulatory receptor for NKG2C. As reported previously, 
NKG2D induced cytolysis of the Fcγ+ P815 mastocytoma 
cell line in a mAb-redirected cytotoxic assay (4), albeit con-
sistently to a lower level than NKG2C (Fig. 2 E).
These fi  ndings demonstrate that NKG2C can substitute for 
the TCR to activate celiac CTLs, and that NKG2D costimu-
lates NKG2C-mediated cytokine secretion and proliferation.
Figure 2.  Expression of functional CD94/NKG2C/DAP12 immuno-
receptor complexes by celiac CTLs. (A) A representative intracellular 
DAP12 staining in TCR-αβ T cells is shown on celiac PB-CTLs. Similar 
results were obtained with freshly purifi  ed celiac NKG2C+ IE-CTLs and 
IE-CTL clones as well as NKG2C+ PB-CTLs from a CMV-seropositive indi-
vidual. (B) Ligation of NKG2C, similarly to CD3, induced ZAP-70 phos-
phorylation in NKG2C+ IE-CTLs. Staining with total anti–ZAP-70 mAb 
demonstrates equal loading. (C and D) NKG2D costimulates NKG2C-
mediated cytokine secretion and proliferation. Fresh NKG2C+ CTLs and 
NKG2C+ CTL lines and clones were incubated with plate-bound mAb, and 
IFN-γ secretion (C) and proliferation (D) were determined by fl  ow 
  cytometry or [3H]thymidine uptake, respectively. Experiments were per-
formed in triplicate, and error bars were <10%. Representative examples 
of three independent experiments are shown. Of interest, CD8 was 
down-regulated upon TCR and NKG2C, but not NKG2D, stimulation in 
freshly isolated IE-CTLs. (E) Anti-NKG2C, similarly to anti-CD3 cross-
linking, induced redirected lysis of P815 target cells by NKG2C+ IE-CTL 
and PB-CTL clones. In all the clones tested, NKG2C was always more 
effi  cient in inducing lysis of P815 targets than NKG2D. In contrast, 
cross-linking with isotype-matched control mAb was ineffective. 
A representative experiment using four NKG2C+ IE-CTL clones 
from the same patient is shown.JEM VOL. 203, May 15, 2006  1347
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HLA-E up-regulation by celiac enterocytes
Interestingly, HLA-E, similarly to MICA/B (4, 5), is not ex-
pressed on the surface of enterocytes in the small bowel of 
normal individuals (n = 10; mean: 0.1 ± 0.2%; P < 0.0001; 
Fig. 3 A). In contrast, fl  ow cytometric analysis revealed that 
HLA-E was massively induced on freshly isolated enterocytes 
of AC patients (n = 5; mean: 36 ± 32.2%), reaching up to 
90% in one patient. Importantly, HLA-E was down-regu-
lated in patients after initiation of a GFD (n = 5; mean: 2.1 ± 
1.4%; P < 0.003), similarly to the previously reported down-
regulation of MICA/B (4, 5). By immunohistochemistry, 
HLA-E was found to be most highly expressed in the entero-
cytes lining the atrophied villi of celiac patients (Fig. 3 B). 
One major inducer of HLA-E is IFN-γ (42), which is highly 
expressed in the intestinal mucosa of AC patients. Indeed, 
IFN-γ induced HLA-E surface expression in three out 
of three enterocyte lines tested (Fig. 3 C). Consistent with 
these observations, preexposure of enterocyte cell lines to 
IFN-γ sensitized them for killing by celiac NKG2C+ CTL 
lines. One apparent exception was INT-407 (Fig. 3 C), 
which was shown to be effi     ciently killed by NKG2D+ 
(NKG2C−) IE-CTLs (4).
Collectively, these data indicate that the expression of 
functional CD94/NKG2C receptors by celiac IE-CTLs is 
met by a corresponding induction of their HLA-E ligand on 
enterocytes, likely contributed in part by increased IFN-γ 
levels in the gut mucosa.
Global NK reprogramming of NKG2C+ celiac CTLs
CD94/NKG2C/DAP12 immunoreceptor complexes are 
normally not expressed in CTLs. Therefore, we hypothesized 
that their expression might be the refl  ection of a more general 
and profound dysregulation of genes related to the NK lineage.
To test this hypothesis, we analyzed the transcriptional phe-
notype of NKG2C+ CTLs using a microarray app  roach in 
combination with fl  ow cytometric and functional analysis.
We fi  rst performed a microarray analysis for gene expres-
sion on NKG2C+ and NKG2C− CTLs. IE-CTL (n = 8) 
and PB-CTL (n = 4) clones were derived from four celiac 
patients. For each of the two IE-CTL samples, two NKG2C+ 
and two NKG2C− clones were analyzed, and the mean gene 
expression level was taken into account for the analysis. In 
addition, one pair of NKG2C+ and NKG2C− CTL clones 
derived from a CMV-seropositive patient (patient 2) was 
  examined, as the presence of functional CD94/NKG2C/
DAP12 receptors was recently reported on the CTLs of these 
individuals (34, 35). The clones were derived from sorted 
single NKG2C+ and NKG2C− cells after only one round of 
Figure 3.  HLA-E up-regulation in celiac enterocytes and killing of 
HLA-E+ enterocytes by celiac CTLs. (A) Flow cytometric analysis 
of freshly isolated enterocytes (ESA+) from AC patients shows surface 
HLA-E expression. The scatter plot summarizes the percentage of HLA-E+ 
enterocytes in control (Cntrl), GFD, and AC patients. (B) Immunohisto-
chemical analysis of HLA-E expression in enterocytes of AC, GFD and 
control patients. A representative example out of fi  ve is shown. (C) HLA-E 
expression by enterocytes cultured overnight in medium alone (UT) 
or with IFN-γ was determined by fl  ow cytometry using anti–HLA-E mAb 
(brown line) or isotype control (blue line). Note that HLA-E was expressed 
signifi  cantly only after stimulation with IFN-γ in the three enterocyte 
lines tested. Interestingly, specifi  c killing of 51Cr-labeled enterocyte 
lines by IE-CTL lines was increased when enterocytes were preincubated 
with IFN-γ.1348  NK REPROGRAMMING OF CTLS | Meresse et al.
expansion (corresponding to 15–18 d of cell culture) to mini-
mize changes associated with long-term cultures. To exclude 
genetic heterogeneity between individuals, comparisons were 
done in a pairwise manner between NKG2C+ and NKG2C− 
clones originating from the same individuals. Two types of 
analysis were completed. A global analysis (Fig. 4 A) com-
paring all NKG2C+ and NKG2C− clones was performed to 
identify genes that were consistently diff  erentially expressed 
by NKG2C+ and NKG2C− CTLs, regardless of their origin. 
In addition, a second analysis was performed on celiac IE-
CTLs and PB-CTLs separately (the CMV-seropositive sam-
ple was excluded) to allow a more specifi  c  analysis  of 
individual cell types and reveal additional diff  erences masked 
by the global analysis (Table S1, available at http://www.
jem.org/cgi/content/full/jem.20060028/DC1).
Strikingly, the global analysis identifi  ed only 40 genes 
that were consistently diff  erentially expressed by NKG2C+ 
and NKG2C− CTLs. Among these 40 genes, 27 could be 
  included into three functionally relevant groups: “NK,” 
“NK and CTL eff  ector function,” and “transformation and 
apoptosis.” The remaining 13 genes were classifi  ed as “other 
genes.” Of interest, among the 40 signifi  cant genes   identifi  ed 
Figure 4.  NK reprogramming in NKG2C+ CTLs. (A) The 40 signifi  cant 
genes obtained by global pairwise microarray analysis of NKG2C+ and 
NKG2C− IE-CTL and PB-CTL clones generated from four celiac patients and 
one CMV-seropositive patient are illustrated. 27 of the 40 genes could be 
clustered into three distinct groups based on their associated function. The 
remaining 13 genes are listed under “Other Genes.” On the left hand side of 
the cluster analysis is the gene name as designated by HGNC. An asterisk (*) 
indicates the inability of the GeneChip to distinguish between the two genes 
(KLRC1 and KLRC2). However, based on data presented in Fig. 1 and analysis 
of NKG2A and NKG2C transcripts by RT-PCR using specifi  c primers, this 
gene was identifi  ed as KLRC2 (NKG2C). On the right hand side of the cluster 
analysis, the fold change between the NKG2C+ and NKG2C− populations is 
shown along with the p-value for a paired t test. Of interest, 10 out of 13 
genes in the NK cluster (highlighted in blue) are all located within the NK 
receptor cluster on chromosome 19q13. (B) This panel highlights the pheno-
typic correlation of the microarray data by multicolor fl  ow cytometry. Rep-
resentative dot plots of NKp46 (NCR1), CD158a (KIR2DL1/KIR2DS1), and 
CD6 expression gated on TCR-αβ+ NKG2C+ populations from fresh normal 
IE-CTLs, NKG2C+ and NKG2C− IE-CTL clones, and fresh PB-CTLs from a 
CMV-seropositive patient are shown. Because CD6 expression in the 
NKG2C− CTL subset of patient 2 (Pt.2) was high, the compensation criteria 
were distinct from those used with the NK receptors NKp46, CD158a, and 
NKp44. This resulted in a lower level of NKG2C staining when anti-NKG2C 
antibody was associated with anti-CD6 antibody. Interestingly, NKG2C+ but 
not NKG2C− CTLs also express NKp44 (NCR2), a result that was not anti-
cipated by microarray analysis. In addition, NKG2C+ CTLs (in red) show 
  increased expression of both perforin and granzyme B compared with 
NKG2C− CTLs (in blue), as suggested by the microarray analysis.JEM VOL. 203, May 15, 2006  1349
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in this study, as many as 19 were related to NK cell pheno-
type and function, a very signifi  cant fi  nding (P < 0.0001), 
highlighting the existence of a specifi  c NK transcriptional 
program associated with NKG2C. As expected, expression 
levels of KLRC2 (NKG2C) and TYROBP (DAP12) genes 
were signifi  cantly increased (8.81-fold change, P = 0.005 
and 27.39-fold change, P = 0.004, respectively) in NKG2C+ 
CTLs. In addition, we found that a much broader set of NK 
receptor genes was increased in NKG2C+ CTLs. These 
  included the C-type lectin receptor NKG2E (KLRC3) and 
the NCR1 receptor NKp46. A very large set of NK recep-
tors of the KIR family was also up-regulated, usually at higher 
levels in PB-CTLs than in IE-CTLs (see Fig. 4 A and Table S1). 
dChip analysis indicated that genes diff  erentially expressed 
between the NKG2C+ and NKG2C− subsets were preferen-
tially localized to chromosome 19q13, which comprises the 
NK cluster encoding immunoglobulin-like NK receptors 
and the NCR NKp46 receptor (P < 0.001; illustrated in Fig. 
4 A in blue). Finally, NKG2C+ CTLs also had increased 
  expression of genes related to cytolytic eff  ector functions, 
  including granulysin, cathepsin W, and perforin 1.
The individual analysis (Table S1) confi  rmed the global 
microarray analysis and revealed the up-regulation of addi-
tional NK-related genes. In addition, it suggested a signifi  -
cant decrease in the transcript levels of both the TCR-α 
(1.56-fold) and TCR-β (3.28-fold) chains (Table S1). This 
latter observation was confi  rmed in eight out of eight clones 
by quantitative RT-PCR, which showed a 4.8-fold decrease 
in the TCR-β transcripts of NKG2C+ (mean: 0.32 ± 0.44; 
range: 0.14–0.55) compared with control NKG2C− IE-
CTLs (mean: 1.53 ± 0.45; range: 0.97–1.93). This intriguing 
fi  nding may relate to the NK reprogramming and is consis-
tent with the down-regulation of TCR by transformed NK-
like CTLs found in refractory celiac sprue (43).
Flow cytometric studies performed on IE-CTLs and PB-
CTLs analyzed by microarray confi  rmed, at the protein level, 
the expression of additional NK receptors and the up-regula-
tion of granzyme and perforin in NKG2C+ CTLs (Fig. 4 B). 
Flow cytometric dot plots of representative molecules that 
were reported to be signifi  cantly down-regulated (CD6) or 
up-regulated (NKp46 [NCR1] and CD158a [KIR2DL1/
S1]) in the global microarray analysis are shown (Fig. 4 B). 
Flow cytometric data on freshly isolated PB-CTLs from the 
CMV-seropositive patient (patient 2) are shown to further 
confi  rm that the NK reprogramming is not an artifact associ-
ated with cell culture. Interestingly, NKp44 expression (an-
other NK receptor associated with DAP12; reference 44) was 
also induced on NKG2C+ cells (Fig. 4 B, right panels), de-
spite RNA expression levels that were apparently similar to 
their NKG2C− counterpart. This observation suggests that 
additional posttranscriptional mechanisms are coordinated 
with transcriptional changes to produce the NK phenotype 
of NKG2C+ CTLs. This is consistent with the fi  nding that 
NKG2C protein is only found in celiac IE-CTLs (Fig. 1 C), 
even though normal IE-CTLs and PB-CTLs express NKG2C 
transcripts (36). Finally, the induction of KIR2DL1/S1 
(CD158a) protein on NKG2C+ CTLs in patient 6, which 
was not anticipated by the global microarray analysis (Fig. 4 A), 
indicates that the extent of induction of NK-associated genes 
in the NKG2C+ CTLs is probably underestimated by this 
global analysis, which is more specifi  c but less sensitive. This 
is supported by the observation that the individual micro-
array analysis revealed the up-regulation of many additional 
NK receptors in IE-CTLs and PB-CTLs. For example, it 
showed an increase in additional KIRs (e.g., KIR2DL2 and 
S2) and CD56 in IE-CTLs, and CD16 and KLRG1 in 
PB-CTLs (Table S1).
Finally, the acquisition of a NK-like phenotype by 
NKG2C+ CTLs was confi  rmed on one hand by analyzing 
their capacity to kill NK targets (Fig. 5) and on the other 
hand by demonstrating that the NK receptors of the NCR 
family NKp44 and NKp46 were functional. As anticipated, 
NKG2C+NKG2D+, but not control NKG2C− NKG2D+, 
celiac CTLs could effi   ciently kill CEM, DAUDI, RAJI, or 
K562 cell lines. Interestingly, IFN-γ treatment of K562 sen-
sitized their killing by NKG2C+. The killing of IFN-
γ–treated K562 and HT-29 cells could only be marginally 
blocked (up to 30%) by anti–HLA-E antibody, HLA-E tetra-
mers, and anti-CD94 and NKG2D antibodies, alone or in 
combination (not depicted), suggesting that multiple activat-
ing NK receptors are involved in the killing of these targets. 
Of interest, individual NKG2C+ CTL clones exhibited vastly 
diff  erent cytolytic profi  les against the diff  erent NK targets. 
These fi  ndings, similar to previous reports on NK cell clones, 
suggested diff  erent assortments of activating and inhibitory 
NK receptors on individual NKG2C+ celiac CTLs and their 
corresponding ligands on diff   erent targets (for review see 
references 45–48). Furthermore, analysis of NCR-mediated 
cytokine secretion and degranulation of cytolytic granules us-
ing plate-bound antibody assays revealed that NKp44 and 
NKp46 were not only expressed, but also functional in 
NKG2C+ CTLs (Fig. 5 B).
Collectively, the phenotypic, functional, and genetic 
analyses of NKG2C+ CTLs indicate that they have acquired 
broad properties of NK cells at the genetic,  phenotypic, and 
functional levels.
TCR repertoire analysis of NKG2C+ CTLs reveals a highly 
restricted repertoire
Because NKG2C has the ability to signal proliferation by itself, 
independently of TCR engagement, we evaluated the level 
of clonal expansion by examining the TCR repertoire of 
NKG2C+ CTLs. A combination of TCR Vβ staining, RT-
PCR, and sequencing, as described previously (36), was applied 
to freshly isolated or short-term cultures of NKG2C+ and 
NKG2− CTLs from fi  ve patients with AC disease and from 
one CMV-seropositive individual. Fig. 6 A shows that in sharp 
contrast with the broad repertoire of the NKG2C− samples, a 
single BV family dominated the TCR repertoire in all three 
NKG2C+ samples. In accordance with previous studies, the 
TCR repertoire of NKG2C+ and NKG2C− CTLs was dis-
tinct (36, 38). The dominant BV was diff  erent in each 1350  NK REPROGRAMMING OF CTLS | Meresse et al.
  individual: BV 8 (42%) in celiac patient 4, BV 5.1 (87%) in 
  celiac patient 8, and BV 16 (76%) in the CMV-seropositive pa-
tient 2. TCR-β chain–specifi  c RT-PCR confi  rmed and ex-
tended these results (Fig. 6 B), showing only six BV families 
(range: 3–11) expressed in NKG2C+ PB-CTLs compared with 
21 expressed in the CD94+ NKG2C− control PB-CTL popu-
lation. In addition, a very restricted number of BV families 
(range: 1–3) was expressed in NKG2C+ IE-CTLs compared 
with CD94+ NKG2C− control IE-CTLs (range: 11–18). In-
terestingly, comparison of the BV families between PB-CTLs 
and IE-CTLs suggested that no BV families were shared be-
tween the two subsets. In particular, sequence nucleotide anal-
ysis of the CDR3 region of BV 6A, the only BV family found 
to be expressed in both PB-CTL and IE-CTL subsets in patient 
5, revealed that the BV6A T cell clones were diff  erent in the 
blood and the intestine. Furthermore, higher resolution analysis 
of the TCR repertoire of PB-CTLs and IE-CTLs expressing 
NKG2C using direct nucleotide sequencing of short-term cell 
cultures (36, 49) demonstrated that nearly all the sequences be-
longed to a few, yet sizeable, clonal expansions. Fig. 6 C shows 
that IE-CTLs and PB-CTLs had an average of 23.7 and 8.9 
transcripts per clone, respectively, indicating that NKG2C+ 
CTLs had undergone massive oligoclonal expansions in 
vivo. No evidence of antigen drive was seen despite a large 
sequencing eff  ort (295 TCR-β chain clonotypes generated).
DISCUSSION
Major expansion of highly activated IFN-γ+ IE-CTLs within 
the atrophic intestinal epithelium is a characteristic compo-
nent of celiac disease (26, 27). Although multiple studies have 
failed to detect gluten-specifi  c responses among these IE-
CTLs, converging reports have recently identifi  ed a dysregu-
lation in the function of NKG2D allowing CTLs to kill 
stressed MICA/B+ enterocytes (4, 5). We now identify in 
celiac patients a population of IE-CTLs with a general and 
lasting alteration of NK receptor expression and function. 
This dysregulation involved expression of activating NK 
  receptors, such as CD94/NKG2C, NKp44, and NKp46, 
considered exclusive NK lineage receptors that can directly 
signal through ITAM-bearing DAP12 and CD3ζ (for review 
see references 48, 50, and 51). The expression of these 
  prototypic activating NK receptors endows CTLs to not only 
Figure 5.  NKG2C+ CTLs kill NK targets and express functional 
Nkp44 and NKp46 receptors. (A) Cytolytic activity of fi  ve NKG2C+ CTL 
clones and one NKG2C−NKG2D+ CTL clone used as control against 51Cr-
labeled NK targets, CEM, DAUDI, RAJI, and K562 is shown at an E/T ratio 
of 50:1. Note that different NKG2C+ CTL clones, similarly to what is ob-
served with NK cells, display distinct pattern of target cell lysis. Interest-
ingly, IFN-γ treatment of K562 augmented their killing by NKG2C+ CTL 
clones. ND, not determined. Experiments were performed in triplicate, 
and error bars were <10%. (B) NKG2C+ PB-CTLs and IE-CTLs were incu-
bated with 5 μg/ml plate-bound antibody or isotype control as indicated. 
IFN-γ production was assessed after overnight stimulation by intracel-
lular fl  ow cytometric analysis, and degranulation of cytolytic granules 
was determined by analysis of surface CD107a expression upon 4 h 
of stimulation.JEM VOL. 203, May 15, 2006  1351
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kill, but also secrete cytokines in an antigen-nonspecifi  c 
  manner. Furthermore, we demonstrate that NKG2C can 
mediate proliferation in CTLs, suggesting that prolifera-
tion is no longer under the control of the TCR.
CD94/NKG2C expression by celiac IE-CTLs appeared 
to be a marker for a general NK reprogramming, as attested 
by the signifi  cant and overall up-regulation of genes belong-
ing to the NK cluster on chromosome 19q13 (P < 0.0001), 
which encodes KIRs, NKp46, and DAP12, and the observa-
tion that out of the 40 genes signifi   cantly increased in 
NKG2C+ CTLs, 19 were related to NK-associated mole-
cules (P < 0.0001). These genetic alterations translated into 
the acquisition of a functional NK phenotype by CTLs, 
whereby a panoply of NK receptors could, alone or in con-
cert, infl  ict damage to the host tissue. For example, NKG2D/
DAP10 costimulated CD94/NKG2C/DAP12-mediated 
  eff  ector functions and proliferation, a fi  nding that is particu-
larly relevant in the context of celiac disease, where both 
MICA/B and HLA-E are induced on celiac enterocytes. Lit-
tle is known at present about the molecular nature of the 
“switch” turning on this NK program in celiac eff  ector 
CTLs. However, extending a recent report that PB-CTLs 
from CMV-seropositive individuals expressed functional 
CD94/NKG2C receptors (35), our detailed genetic and 
functional studies of one CMV-seropositive individual would 
indicate that several infl  ammatory conditions might lead to a 
similar NK reprogramming of CTLs. Collectively, our past 
(4) and present observations give a molecular basis to older 
studies reporting that CTL clones can be induced under par-
ticular culture conditions to exert “promiscuous,” antigen-
nonspecifi  c killing (52–54).
There are striking parallels between the existence of 
  reprogrammed CTLs and the characteristic complications of 
celiac disease, refractory sprue, and enteropathy-associated 
Figure 6.  NKG2C+ CTLs display a highly restricted TCR repertoire. 
(A) TCR-β chain repertoire analysis of CD8+ NKG2C+ and NKG2C− popula-
tions from two AC disease samples and one PB-CTL sample from a CMV-
seropositive patient by fl  ow cytometry is shown. Results are expressed as 
percentages of TCR-β chain+ cells among CD8+TCR-αβ+ T cells. (B) TCR-β 
chain repertoire analysis by RT-PCR analysis of representative PB-CTL and 
IE-CTL samples from AC patients, PB-CTLs from a CMV-seropositive patient, 
and representative CD94+ NKG2C− control CTL samples matched for the 
effector/memory status (expression of CD45 RO and RA, CCR7, CD62L, and 
capacity to mediate TCR cytolysis). The TCR repertoire is represented by a 
grid that contains 25 separate boxes, each signifying a TCR-β chain vari-
able region (BV) gene family (BV1-BV25). Gray shaded boxes indicate that 
the corresponding TCR BV gene is expressed. Patient 5 (Pt.5) has paired PB-
CTL and IE-CTL samples obtained at the same time. Notably, patient 2 (Pt.2) 
illustrates that a similar result was obtained by both fl  ow cytometry and 
RT-PCR. TCR nomenclature is designated by Arden et al. (reference 66). 
(C) This panel summarizes the 295 β chain nucleotide sequences obtained 
by sequencing 10 TCR BV families from three PB-CTL and two IE-CTL celiac 
samples. The CTL populations are represented by both the number of tran-
scripts (TCR-β chain sequences) and the number of clones. Expanded 
clones contain two or more identical β chain sequences, whereas clonal 
size represents the average number of sequences per clone.1352  NK REPROGRAMMING OF CTLS | Meresse et al.
T cell lymphoma (EATL). In accordance with the expression 
of CD94 (55) and the NK-like properties (56) reported for 
refractory IE-CTLs, we have found expression of functional 
CD94/NKG2C receptors in two out of two refractory sprue 
patients examined (not depicted). The TCR studies of the 
CD94/NKG2C+ IE-CTL subset in “uncomplicated” celiac 
patients, as reported here, clearly established that these repro-
grammed CTLs had undergone signifi  cant clonal expansions, 
suggesting that by enabling CTL proliferation through 
TCR-independent NK receptor–mediated mechanisms, re-
programming may be the direct cause of these chronic un-
controlled expansions. Together with the dysregulation of 
genes associated with cell transformation (e.g., LYN and 
HRASLS3), these fi  ndings may suggest that the NKG2C+ 
IE-CTLs can ultimately undergo malignant transformation. 
Likewise, the reduction of TCR-α and TCR-β transcripts 
may represent a mechanism explaining the low or absent 
  surface TCR expression reported in a subset of refractory 
sprue and EATL lymphomas (43). Future prospective studies 
correlating the presence of NK reprogramming with the 
  severity of disease, the resistance to GFD, and the incidence 
of refractory sprue or EATL will test the predictive value of 
these changes. Detailed analysis of the massive clonal expan-
sions of CD94/NKG2C+ IE-CTLs in patients developing 
diet-refractory disease may also lead to further insights into 
the transformation process.
In addition to novel insights into the pathology of celiac 
disease, our fi  ndings have implications on the diff  erentiation 
and selection of the T cell and NK cell lineage. Indeed, al-
though CTLs and NK cells are the two prominent lymphoid 
subsets in charge of cytolytic function within the vertebrate 
immune system, they follow fundamentally diff  erent rules for 
cellular activation and tolerance. Whereas CTLs use diversely 
rearranged TCRs to focus on rapidly evolving microbial 
peptides, NK cells use a limited set of germline-encoded re-
ceptors to recognize conserved stress-induced self-ligands as 
stimuli to rid infectious agents. CTL tolerance applies to cells 
bearing self-specifi  c TCRs, whereas NK cell tolerance ap-
plies to cells lacking appropriate self-specifi  c inhibitory re-
ceptors (57). In this context, the existence of CTL/NK 
hybrid cell types raises several important functional issues. 
For example, activating NK receptors, such as CD94/
NKG2C, NKp44, and NKp46, which signal directly through 
ITAM-bearing DAP12, CD3ζ, or FcεRIγ, could potentially 
interfere with normal T cell tolerance mechanisms by induc-
ing the expansion and unleashing the eff  ector functions of 
CTLs. Thus, several recent studies have investigated the ex-
tent of NK lineage receptor expression by subsets of eff  ector/
memory CTLs, the mechanisms of signal integration between 
TCR and NK receptors, and the potential consequences in 
health and disease. These studies have uniformly emphasized 
that NK lineage receptors expressed in CTLs were restricted 
to those serving a costimulatory and inhibitory function for 
TCR signaling in eff  ector/memory CTLs, similar to the role 
of CD28 and CTLA-4 in naive T cells (for review see 
references 1 and 58). These NK receptors enhanced or pre-
vented TCR-mediated cytolysis based on stress- or infl  am-
mation-induced expression of NK receptor ligands by the 
target cell. This new layer of regulation of adaptive immunity 
through innate signals emitted by the target itself serves a dual 
role of enhancing cytolysis of cells that are infected while pre-
serving those healthy cells that might express cross-reactive 
self-antigens.
We speculate that the graded induction of NK lineage 
features and ultimately the functional transformation of 
CTLs into NK-like cells may represent a dysregulation of the 
adaptive immune response induced under conditions of 
chronic activation (59) and resulting in the reversal to innate 
modes of immune defense. Although it is advantageous to 
enhance the ability of CTLs to eradicate cells undergoing 
stress even in the presence of low or undetectable antigen, 
this rather indiscriminate mode of defense may ultimately 
lead to chronic forms of infl  ammation and disease. Under-
standing the mechanisms leading to this stepwise reprogram-
ming of CTLs may shed new light on these chronic infectious 
and infl  ammatory diseases, as well as suggest therapies better 
suited to treat them.
MATERIALS AND METHODS
Patients and controls. Diagnosis of celiac disease was based on detection 
of anti-transglutaminase antibodies, the presence of HLA DQ2 or DQ8, 
villous atrophy, and clinical and histological response to GFD. 27 individu-
als had AC disease with partial villous atrophy, whereas 16 were on a strict 
GFD for 1–3 yr. The GFD patients had become negative for anti-transglu-
taminase antibodies and recovered a normal or subnormal villous architecture. 
16 individuals undergoing either gastric bypass for morbid obesity or 
  endoscopies and biopsies for functional intestinal disorders of nonceliac 
  origin, as described previously (37, 60), were studied as controls. Lympho-
cytes and epithelial cells were isolated from biopsies or surgical specimens. 
PBLs were isolated from whole blood from celiac patients and healthy 
  donors. Standard diagnostic tests were used to identify among healthy donors 
individuals with circulating IgG antibodies against CMV (Abbot   Laboratories). 
All subjects gave written informed consent, and research was approved by 
institutional review boards.
Cell isolation, cell lines generation, and cell culture. IE-CTLs and 
enterocytes were purifi  ed from jejunal biopsies as described previously (4). 
PBLs were isolated from whole blood after Ficoll density gradient centrifu-
gation (GE Healthcare). After sorting, NKG2C+NKG2D+TCR-αβ+CD8+ 
IE-CTLs and PB-CTLs, and NKG2C−NKG2D+TCR-αβ+CD8+ IE-CTL 
lines or clones were obtained from celiac patients and one CMV-seroposi-
tive individual, as described previously (4). Epithelial intestinal cell lines 
HUTU-80, INT-407, and HT-29, the NK target cell lines CEM, DAUDI, 
RAJI, and K562, and the FcγR+ mouse mastocytoma P815 (American 
Type Culture Collection) were cultured in RPMI-1640 medium with 10% 
FCS and antibiotics.
Flow cytometric analysis. Fluorochrome-conjugated anti-CD3, anti-CD8, 
anti–TCR-αβ, anti-CD103, anti-CD94, anti–IFN-γ, and anti-CD107a were 
purchased from BD Biosciences. Anti-NKG2A, anti-NKp44, and anti-NKp46 
were purchased from Immunotech. Anti-NKG2C (clone 591) was from R&D 
Systems, and FITC-conjugated anti-epithelial–  specifi   c antigen was from 
Biomeda. For TCR repertoire analysis, PE-conjugated anti-TCRVβ antibod-
ies were purchased from BD Biosciences. Anti-DAP12 (DX37; reference 30) 
and anti-HLA-E (3D12; reference 61) antibodies as well as HLA-E tetramers 
loaded with the HLA-G leader peptide (32) were generated.JEM VOL. 203, May 15, 2006  1353
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For surface staining, cells were incubated with fl  uorochrome-conju-
gated antibodies according to standard protocols. Unconjugated antibodies 
were revealed with appropriate fl  uorochrome-conjugated F (ab′)2 goat anti–
mouse IgG isotype from SouthernBiotech.
For intracellular staining, cells were fi  xed and permeabilized using a BD 
Biosciences kit. Fluorescence was analyzed on a four-color FACSCalibur 
(Becton Dickinson) with quadrants set to score as negative >99% of control 
Ig-stained cells.
Immunohistochemistry. HLA-E staining was performed as described 
previously (62), using the anti–HLA-E antibody 3D12 and IgG1 isotype-
matched control antibody on 4-μm cryostat sections from small intestinal 
biopsies embedded in OCT compound (Sakura Fine Technologies) and 
snap-frozen in liquid nitrogen. Antibody binding was detected using horse-
radish peroxidase–labeled secondary anti–mouse IgG antibody (EnVision 
System; DakoCytomation) and DAB chromogen. Sections were counter-
stained with Gill’s 3 hematoxylin, and coverslips were attached by using 
Sub-X mounting medium (Surgipath).
Cytotoxicity and degranulation assays. 51Chromium-release assays 
were performed as described previously (4), using intestinal epithelial target 
cells and the mouse Fcγ+ mastocytoma P815 cell lines at an E/T ratio of 
50:1, unless otherwise stated. All experiments were performed in triplicate, 
and error bars were <10%. In some experiments, epithelial cells or K562 
cells were cultured with 15 ng/ml IFN-γ (BD Biosciences) for 12 h. For 
  antibody-dependent cytotoxicity, eff  ectors and targets were incubated in 
the presence of soluble anti-NKG2C, anti-CD3, or control mouse IgG1 
mAbs. Chromium release was measured using a scintillation counter (Packard 
Instrument Co.). The percentage of specifi  c cytotoxicity was calculated 
  using the following formula: 100 × (cpm experimental − cpm spontaneous)/
(cpm maximum − cpm spontaneous).
Degranulation was assayed using fl  ow cytometric quantifi  cation of the 
surface mobilization of CD107a, a membrane protein present in cytolytic 
granules, as described previously (63, 64). In brief, T cells were stimulated 
with plate-bound anti-NKp44 (clone 253415; R&D Systems), anti-NKp46 
(clone 195314; R&D Systems), anti-CD3 (BD Biosciences) mAbs, or iso-
type control (BD Biosciences) for 4 h at 37°C. Cells were then stained with 
anti-CD107a mAb in PBS, 2 mM EDTA.
IFN-𝗄 production. Freshly isolated cells or NKG2C+ T cell clones were 
cultured for 12 h with brefeldin A (GolgiPlug; BD Biosciences) in fl  at-
  bottom 96-well plates precoated overnight with 10 μg/ml anti-CD3, 
anti-NKG2D (1D11), anti-NKG2C (591), anti-NKp44 (clone 253415), or 
anti-NKp46 (clone 195314) antibody and a mouse IgG isotype-matched 
control, alone or in combination. Cells were fi  xed and permeabilized using 
a BD Biosciences kit, stained with FITC-conjugated anti–IFN-γ antibody 
or isotype-matched control IgG, and analyzed by fl  ow cytometry.
Proliferation assay. Intraepithelial lymphocyte clones (2 × 105 cells/well) 
were cultured in 96-well fl  at-bottomed plates precoated with anti-CD3 or 
anti-NKG2C antibody at the indicated concentration, alone or in associa-
tion with anti-NKG2D antibody or control Ig at 10 μg/ml. After 48 h of 
culture, [3H]thymidine (0.5 mCi/well; MP Biomedicals) was added and 
plates were cultured for an additional 24 h. The results are shown as the 
mean of triplicate wells. Error bars were always <10%.
ZAP-70 phosphorylation. CD8+TCR-αβ+NKG2C+ clones were serum 
starved 30 h before stimulation. To cross-link immunoreceptors, cells were 
incubated at 37°C with isotype-matched control Ig, anti-CD3, anti-
NKG2D, or anti-NKG2C before adding goat anti–mouse IgG F (ab′)2 frag-
ments for the indicated duration. Cells were lysed for 20 min in a lysis buff  er 
containing freshly added protease and phosphatase inhibitors (50 mM Tris 
HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM 
Na3VO4, 1 mM NaF, and protease inhibitor cocktail tablets). Equal amounts 
of protein were subjected to SDS-PAGE under reducing conditions in 
10% gels, transferred to nitrocellulose membranes (Bio-Rad Laboratories), 
and probed with anti-phospho–ZAP-70 serum (Cell Signaling Technology) 
  followed by horseradish peroxidase–conjugated donkey anti–rabbit IgG 
(Jackson ImmunoResearch Laboratories). To control for loading diff  erences, 
blots were stripped and reprobed with an anti–ZAP-70 antibody (Cell Sig-
naling Technology). Binding of secondary antibodies was visualized using 
the enhanced chemiluminescence ECL kit from GE Healthcare.
Microarray hybridization. Using a standard GeneChip preparation pro-
tocol (Aff  ymetrix, Inc.; reference 65), gene array hybridizations and data 
collection on selected NKG2C+ and NKG2C− IE-CTL and PB-CTL sam-
ples were preformed at the Functional Genomics Facility, University of 
  Chicago. In brief, 10 μg total RNA, extracted using the RNeasy Mini kit 
(QIAGEN), was used to generate double-stranded cDNA using a T7-linked 
oligo dT primer and the Superscript II RT system (Invitrogen). Purifi  ed 
cDNA was then used to generate biotin-labeled cRNA using the BioArray 
High Yield RNA Transcript Labeling kit (Enzo Diagnostics) according to 
the manufacturer’s protocol. This biotinylated cRNA was then fragmented 
and hybridized to Aff  ymetrix GeneChip HG-U133. The arrays were then 
washed and stained with phycoerythrin-conjugated streptavidin according 
to the Aff  ymetrix GeneChip protocol and scanned using the Aff  ymetrix 
  Agilent GeneArray Scanner.
Microarray data analysis. Data analyses were preformed using DNA-Chip 
Analyzer 1.3 (dChip; reference 65) with the *.CEL fi   les obtained from 
GeneChip Operating System 1.3 (GCOS 1.3). A PM-only model was used to 
estimate gene expression level, and the invariant set approach was used for 
normalization. For comparison analyses of the paired NKG2C+ and NKG2C− 
populations, thresholds for selecting signifi  cant genes were set at a relative dif-
ference of >1.5 fold, absolute diff  erence of >100, and a signifi  cant paired 
t test for the signal intensity diff  erence at P < 0.05. Duplicate genes and genes 
of unknown function were removed. The remaining genes were then grouped 
based on function, and cluster analysis was preformed using dChip (65).
TCR repertoire analysis. RNA was isolated and fi  rst-strand cDNA template 
was prepared from CD94+ (control) and NKG2C+ IE-CTLs and PB-CTLs as 
described previously (36). Using standardized amounts of starting template, 
TCR-β chain variable region (BV) PCR was performed as described previ-
ously (49). For nucleotide sequence analysis of certain TCR BV family reper-
toires, selected BV region families were cloned and sequenced, as described 
previously (49). The 295 TCR-β chain nucleotide sequences obtained were 
analyzed within each BV family, and CDR3 motifs with identical sequences 
were grouped together to show TCR clonotypes as described previously (49). 
For simplicity, a clone was considered expanded if two or more identical 
TCR-β chain sequences were identifi  ed during sequence analysis (49). In this 
study, we used the TCR BV nomenclature proposed by Arden et al. (66) for 
correlation with the anti-BV mAb specifi  cities. Correspondence between the 
Arden and HGNC nomenclatures can be found at http://imgt.cines.fr (67).
Quantitative RT-PCR. Quantitative real-time RT-PCR was preformed us-
ing the iCycler iQ real-time PCR detection system (Bio-Rad Laboratories) and 
an SYBR green amplifi  cation kit (PE Biosystems). To confi  rm that the same 
amount of starting template was used in each BV PCR reaction, the quantity 
was standardized using GAPDH primers, as described previously (4). For com-
parison of the relative levels of TCR expression between NKG2C+ and con-
trol CD94+ IE-CTL populations, we used primers specifi  c for the constant 
region of the TCR-β chain and normalized their expression against GAPDH 
levels, as described previously (4), using 10 μm of the following primers with 
an annealing temperature of 56°C: 5′-A  G  C  C  C  G  C  C  C  T  C  A  A  T  G  A  C  T  C  C- 
A  G  A  T  A  C  T  -3′ and 5′-A  T  A-    G  A  G  G  A  T  G  G  T  G  G  C  A  G  A  C  A  G  G  A  C  -3′.
Statistical analysis. All expression data were transformed from percent-
ages to natural logarithms of the percentages to reduce the heterogeneity of 1354  NK REPROGRAMMING OF CTLS | Meresse et al.
variance across the AC disease, GFD, and control groups. Analyses of vari-
ance 2-degree-of-freedom F-tests were constructed to test for diff  erences in 
log expression across the three groups. Where F-tests were signifi  cant at 
the α = 0.05 level, mean pairwise comparisons were tested with a Tukey 
multiple comparisons correction.
A Fisher’s exact test was used to determine the probability that 19 out 
of 46 genes found to be up-regulated by microarray analysis were NK-
related genes. This test conditions on the fact that 16,500 were functional 
genes, of which 150 were NK genes, and that 46 genes of the 16,500 were 
up-regulated in NKG2C+ CTLs. The p-value reports the probability that 
19 or more NK genes would be signifi   cantly expressed under the null 
hypothesis that NK genes are not overexpressed in NKG2C+ cells as com-
pared with NKG2C− cells. All statistic analysis was performed using SAS 
(SAS 2002–2005; SAS Institute).
Online supplemental material. The sequence of all TCR-β chain clono-
types obtained in this study can be accessed with the following accession 
numbers: DQ473356 and DQ473390. All microarray data can be accessed 
using the National Center for Biotechnology Information GEO accession 
number GSE4592. Table S1 shows data expressed as fold-change for selected 
genes that were obtained when comparing separately IE-CTL and PB-CTL 
NKG2C+ and NKG2C− celiac clones. Table S1 is available at http:// www.
jem.org/cgi/content/full/jem.20060028/DC1.
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